San Francisco, United States
Loyal, operating under the umbrella of Cellular Longevity, is a promising player in the biotechnology industry, founded in 2019 and headquartered in the United States. The company is pioneering the development of drugs aimed explicitly at extending the healthspan and lifespan of dogs, with future plans to translate this innovation to human applications.
The company's mission is grounded in the scientific approach of quantifying and controlling aging mechanisms to delay age-related diseases, potentially adding more healthy years to life for both animals and humans. The upcoming product launch targets canine longevity and health.
Recently, Loyal successfully closed a $45.00M Series B investment round on March 21, 2024, attracting notable investors such as BoxGroup, Bain Capital Ventures, First Round Capital, Khosla Ventures, Valor Equity Partners, Collaborative Fund, Quiet Capital, and The Todd & Rahul Angel Fund. This robust backing highlights both a strong industry trust and significant growth potential for Loyal in the longevity market.
